Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis

被引:58
|
作者
Ahluwalia, Vishwadeep [1 ,2 ,3 ]
Heuman, Douglas M. [1 ,2 ]
Feldman, George [2 ,4 ]
Wade, James B. [2 ,5 ]
Thacker, Leroy R. [2 ,6 ]
Gavis, Edith [1 ,2 ]
Gilles, HoChong [1 ,2 ]
Unser, Ariel [1 ,2 ]
White, Melanie B. [1 ,2 ]
Bajaj, Jasmohan S. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Dept Gastroenterol Hepatol & Nutr, Richmond, VA 23221 USA
[2] McGuire VA Med Ctr, Richmond, VA 23221 USA
[3] Virginia Commonwealth Univ, Dept Radiol, Richmond, VA 23221 USA
[4] Virginia Commonwealth Univ, Dept Nephrol, Richmond, VA 23221 USA
[5] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23221 USA
[6] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23221 USA
关键词
Caregiver burden; Aquaresis; Diffusion tensor imaging; Hepatic encephalopathy; Magnetic resonance spectroscopy; Tolvaptan; HEPATIC-ENCEPHALOPATHY; VASOPRESSIN ANTAGONIST; HEALTH; HYPERAMMONEMIA; TOLVAPTAN; BURDEN;
D O I
10.1016/j.jhep.2014.07.033
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Hyponatraemia in cirrhosis is associated with impaired cognition and poor health-related quality of life (HRQOL). However, the benefit of hyponatraemia correction is unclear. The aim of this study was to evaluate the effect of tolvaptan on serum sodium (Na), cognition, HRQOL, companion burden, and brain MRI (volumetrics, spectroscopy, and diffusion tensor imaging) in cirrhotics with hyponatraemia. Methods: Cirrhotics with Na <130 mEq/L were included for a four-week trial. At screening, patients underwent cognitive and HRQOL testing, serum/urine chemistries and companion burden assessment. Patients then underwent fluid restriction and diuretic withdrawal for two weeks after which cognitive tests were repeated. If Na was still <130 mEq/L, brain magnetic resonance imaging (MRI) was performed and tolvaptan was initiated for 14 days with frequent clinical/laboratory monitoring. After 14 days of tolvaptan, all tests were repeated. Comparisons were made between screen, pre- and post-drug periods Na, urine/serum laboratories, cognition, HRQOL and companion burden. Results: 24 cirrhotics were enrolled; seven normalized Na without tolvaptan with improvement in cognition. The remaining 17 received tolvaptan of which 14 completed the study over 13 +/- 2 days (age 58 +/- 6 years, MELD 17, 55% HCV, median 26 mg/day of tolvaptan). Serum Na and urine free water clearance increased with tolvaptan without changes in mental status or liver function. Cognitive function, HRQOL and companion burden only improved in these 14 patients after tolvaptan, along with reduced total brain and white matter volume, increase in choline on magnetic resonance spectroscopy, and reduced cytotoxic oedema. Conclusions: Short-term tolvaptan therapy is well tolerated in cirrhosis. Hyponatraemia correction is associated with cognitive, HRQOL, brain MRI and companion burden improvement. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [31] Adalimumab improves quality of life
    Konstantinos A. Papadakis
    Nature Reviews Gastroenterology & Hepatology, 2009, 6 : 200 - 201
  • [32] Quality of Life of Patients with Liver Cirrhosis
    Villavicencio, Marfa Belen Alvarado
    Rubio, Evelyn Carolina Betancourt
    Ponce, Luis Roberto Villamarfn
    FINLAY, 2023, 13 (03): : 149 - 164
  • [33] Hepatitis C virus eradication improves cognition in patients with and without cirrhosis: results from a real-life prospective study
    Ibanez, Luis
    Rapado, Marta
    Cabrero, Lucia
    Navarrete, Cristina
    Garcia-Mulas, Seila
    Ahumada, Adriana
    Laura, Marquez
    Dolores Perez, Maria
    Rincon Rodriguez, Diego
    Banares, Rafael
    Garcia Martinez, Rita
    JOURNAL OF HEPATOLOGY, 2021, 75 : S784 - S785
  • [34] Erlotinib improves quality of life
    Susman, Ed
    LANCET ONCOLOGY, 2006, 7 (10): : 802 - 802
  • [35] Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis
    Xiaoning Wu
    Jia Hong
    Jialing Zhou
    Yameng Sun
    Lei Li
    Wen Xie
    Hongxin Piao
    Xiaoyuan Xu
    Wei Jiang
    Bo Feng
    Yongpeng Chen
    Mingyi Xu
    Jilin Cheng
    Tongtong Meng
    Bingqiong Wang
    Shuyan Chen
    Yuanyuan Kong
    Xiaojuan Ou
    Hong You
    Jidong Jia
    Hepatology International, 2021, 15 : 1318 - 1327
  • [36] Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis
    Wu, Xiaoning
    Hong, Jia
    Zhou, Jialing
    Sun, Yameng
    Li, Lei
    Xie, Wen
    Piao, Hongxin
    Xu, Xiaoyuan
    Jiang, Wei
    Feng, Bo
    Chen, Yongpeng
    Xu, Mingyi
    Cheng, Jilin
    Meng, Tongtong
    Wang, Bingqiong
    Chen, Shuyan
    Kong, Yuanyuan
    Ou, Xiaojuan
    You, Hong
    Jia, Jidong
    HEPATOLOGY INTERNATIONAL, 2021, 15 (06) : 1318 - 1327
  • [37] Exercise, brain, and cognition across the life span
    Voss, Michelle W.
    Nagamatsu, Lindsay S.
    Liu-Ambrose, Teresa
    Kramer, Arthur F.
    JOURNAL OF APPLIED PHYSIOLOGY, 2011, 111 (05) : 1505 - 1513
  • [38] Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosis
    Fritz, Nora E.
    Roy, Snehashis
    Keller, Jennifer
    Prince, Jerry
    Calabresi, Peter A.
    Zackowski, Kathleen M.
    NEUROREHABILITATION, 2016, 39 (04) : 535 - 544
  • [39] Progressive multiple sclerosis in Chile: Demographics, disability, cognition, brain atrophy, and quality of life measures
    Ciampi, Ethel
    Uribe, Reinaldo
    Carcamo, Claudia
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 144 - 145
  • [40] Vascular endothelial growth factor labelling index in brain tumours: Correlation with proliferation rate, oedema and quality of life
    Lafuente, JV
    Rossi, M
    Garibi, J
    Pomposo, I
    BRAIN PATHOLOGY, 2000, 10 (04) : 734 - 734